Mounjaro Weight Loss Injection

  • buy mounjaro online

Images for illustration purposes only. Brands may vary.

Availability

In Stock

Fastest delivery available: 19/04/2024

For more information on our delivery times, please click here

Order it within: 24 hours

Pricing and quantity options

Orlistat 120mg Capsules

Strength
Quantities
Quantities 120mg
42 £17.39
84 £33.98
168 £67.96
252 £98.99

Saxenda Weight Loss Pen

Strength
Quantities
Quantities 3mg

Saxenda Weight Loss Pen

Strength
Quantities
Quantities 3mg

Wegovy (Semaglutide) Weight Loss Injection

Strength
Quantities
Quantities Weeks 1-4: 0.25mg
1 Month £159.00
Quantities Weeks 5-8: 0.5mg
1 Month £159.00
Quantities Weeks 9-12: 1.0mg
1 Month £165.00
Quantities Weeks 13-16: 1.7mg
1 Month £219.00
Quantities Weeks 17 onwards: 2.4mg
1 Month £259.00
Quantities Starter Packs
2 Months - 0.25mg & 0.5mg £319.00
3 Months - 0.25mg & 0.5mg & 1.0mg £469.00

Mysimba

Strength
Quantities
Quantities 8mg/90mg
112 £109.00

Xenical 120mg Capsules

Strength
Quantities
Quantities 120mg
42 £29.98
84 £44.50
168 £87.99
252 £130.50

Mounjaro Weight Loss Injection

Strength
Quantities
Quantities Starting Dose 2.5mg
1 Month £158.99
Quantities 5mg
1 Month £164.99
Quantities 7.5mg
Quantities 10mg
Quantities 12.5mg
Quantities 15mg
Quantities Starter Pack 2.5mg & 5mg
2 Month Starter Pack £300.00
Qty1 Month
Price£158.99
Qty2 Month Starter Pack
Price£300.00
Qty1 Month
Price£164.99
Qty
Price
Qty
Price
Qty
Price
Qty
Price
Registered UK Pharmacy number 9012073
Please note: This page is only to be used as a reference of our price for this medication. If you are approved you will be offered treatment for you and the prescriber to jointly consider. However, the final decision will always be the prescriber's.

Medication features

 Mounjaro™ is a once-weekly injectable weight loss aid that is often prescribed when other weight loss efforts have been ineffective. It works by acting on the hormones responsible for appetite control and blood sugar. This in turn reduces the feeling of hunger and improves blood sugar levels. 

We provide confidential follow-up and advice to all patients on their weight loss journey.

 

 

View product details
  • Once Weekly Injection
  • Clinically Proven
  • Same family as Wegovy
  • Feel fuller for longer by targeting two receptors
  • Trials show ~20% body weight loss

Overview
Learn moreicon-arrow-right
Close

Buy Mounjaro™ Online UK

The active ingredient in Mounjaro weight loss injection is Tirzapetide and be purchased from our UK registered online prescribing service. Mounjaro was launched in the UK in February 2024, and is the latest GLP-1 weight loss treatment available. You will be able to order Mounjaro following an online assessment with our qualified medical team. If a prescription is suitable, this is passed to our pharmacy team, who dispense and discreetly package your treatment.

 Like the Wegovy weight loss pen it is an injection that can be used to suppress your appetite and therefore aid in your weight loss journey. Studies showed that Mounjaro helped people lose an additional 12 pounds than the active ingredient Semaglutide (Wegovy™). It is not yet fully understood on how patients can switch from Wegovy to Mounjaro. The most likely scenario will be that a patient will have to wait for 14 days after their latest Wegovy dose, and start Mounjaro from 2.5mg.

What is Mounjaro™ Weight Loss Injection?

Mounjaro™ is a prescription-only weight loss injection containing the active ingredient Mounjaro™ Tirzepatide. This is a registered trademark to Eli Lilly who are an american based pharmaceutical company. It is known as Zepbound in the USA. 

The Mounjaro™ (Tirzepatide) injection is an injectable prescription medicine used for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also have weight-related medical problems (e.g high blood pressure, type-2-diabetes, high cholesterol) to help them lose weight and keep the weight off.

  • Mounjaro™ should only be used with a reduced calorie meal plan and regular exercise. Mounjaro™ alone will not reduce your weight if taken alone without any other life style adjustments.
  • Mounjaro™ contains Tirzepatide, a GLP-1 receptor agonist & GIP receptor agonist and should NOT be used in conjunction with other GLP-1 agonists such as Saxenda or Ozempic or Wegovy.
  • There is insufficient data regarding whether taking Mounjaro™ in conjunction with other prescription, over-the-counter or herbal weight loss products is safe and/or effective.

How Does Mounjaro™ Work?

Mounjaro™ (Tirzepatide) is a self-injectable weight loss treatment. It containts the active ingredient Tirzepatide which is very similar to a naturally occuring hormone in the human body called Glucagon-Like Peptide 1 (GLP-1), which belongs to a family of hormones in the body called incretins.

After a meal GLP-1 is naturally released from your intestines to help regulate your blood sugar levels and reduce the amount of glucagon in your body. Glucagon is a naturally occurring hormone that works by inhibiting the action of insulin. As a result, it makes you feel less hungry, slows down the emptying of your stomach and makes you feel 'fuller' for longer.

In summary, Mounjaro™ 'tricks' your body into producing more GLP-1 and therefore sends signals to your brain that you are full and do not need to eat. 

How Effective is Mounjaro™?

When using Mounjaro kwikpens to suppress appetite, you can expect to lose around 15-20% of your initial body weight after completing treatment with a balanced diet and exercise. This is the most effective of all the released GLP-1 medications so far including Wegovy.

These figures have been achieved by patients who have maintained on the highest strength of Mounjaro, which is the 15mg strength.

In a trial carried out by Eli Lilly, it was shown that patients who maintained dose at 10mg lost an average of 17% of their body weight whilst patients who maintained dose at 5mg, lost around 15%.

Mounjaro vs Ozempic (Wegovy)

Can Mounjaro™ Help me Lose Weight?

The second phase 3 clinical trial for Mounjaro™ conducted by Eli Lilly and Company saw 900 patients with with type 2 diabetes and BMI greater than 27 kg/m2-29.9 kg/m2. Patients received Mounjaro™ or placebo in addition to instruction for a reduced-calorie diet (approximately 500 kcal/day deficit) and increased physical activity counseling (recommended to a minimum of 150 min/week) throughout the trial.

The trial resulted in a satistically significant reduction in body weight when compared to the placebo. The trial showed that there was an average reduction of 15.7% in body weight in patients taking Mounjaro vs 3.3% reduction in body weight for those taking the placebo.

The results also indicated that after 72 weeks on Mounjaro™, over 80% of patients lost 5% or more of their body wieght. In the placebo group, 30% of patients lost 5% or more. Further clinical trials were also carried out in participants who did not have Type 2 diabetes, which showed statistically significant reductions in body weight.

Mounjaro™ Vs Saxenda

Saxenda® (liraglutide) injection 3 mg is an injectable prescription medicine that may help some adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30) lose weight and keep the weight off. Saxenda® should be used with a reduced-calorie meal plan and increased physical activity.

Both Mounjaro™ and Saxenda® are GLP-1 receptor agonists, and are part of the same family of injectable hormone like drugs, however the main difference between the two is that Saxenda® is administered once DAILY, whereas Mounjaro™ is administered once WEEKLY.

Mounjaro™ Vs Wegovy®

Tirzepatide (Mounjaro) is a type of medication that belongs to the class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RA) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. This group of medications is primarily used in the treatment of type 2 diabetes. 


Mounjaro works by imitating the effects of gut hormones that are secreted by endocrine cells following a meal, such as GLP-1 and GIP, which help control regulation of blood sugar. Mounjaro helps to stimulate the release of insulin, reduces the overall production of glucagon, (a hormone that raises blood sugar), slows down gastric emptying and promotes the feeling of fullness (satiety).


Mounjaro has shown promising levels of efficacy for weight loss in clinical trials. In Phase 2 trials involving subjects who were either obese or overweight, Mounjaro led to significant reductions in body weight compared to the placebo and other comparator treatments. Mounjaro is typically administered once a week, by subcutaneous injection.


For example, in a trial called SURPASS-1, Mounjaro achieved an average weight loss of approximately 14% over 52 weeks. In another study called SURMOUNT-1, subjects that were treated with Mounjaro experienced an average weight loss ranging from 11.3% to 16% across different doses compared to placebo. 


Wegovy® is the brand name for semaglutide 2.4mg. Wegovy® is a medication used for chronic weight management in adults who are either obese or overweight, with at least one weight-related comorbidity. It is a GLP-1 RA that helps to regulate appetite and reduce food consumption. 


Wegovy® is administered once a week by subcutaneous injection; research has shown that when used in combination with a calorie controlled diet and increased physical activity, significant weight loss is seen.


In a study called STEP 1, subjects that received semaglutide 2.4mg experienced an average weight loss of around 15% compared to the placebo group. The same study also noted improvements in various health markers such as waist circumference and improved glycemic control.


Comparing the efficacy of Mounjaro and Wegovy® directly is challenging because they are different medications with varying dosages and mechanisms of action, however, both of these medications are GLP-1 RA and have shown efficacious effects when managing weight loss in clinical trials.


Mounjaro:


Clinical trials have demonstrated the efficacy of Mounjaro for weight loss. Studies such as SURPASS-1 and SURMOUNT-1, previously mentioned, have demonstrated that Mounjaro achieved significant weight loss ranging from 11.3% to 16.0% over 52 weeks when compared to a placebo or other treatments in the same category. Mounjaro has also shown potential for weight reduction as well as benefits in glycemic control and cardiovascular risk factors.


Wegovy®:


Semaglutide 2.4mg (Wegovy®) has also shown notable effectiveness for weight loss in clinical trials. In the STEP program (consisting of trials STEP 1, STEP 2 and STEP 3), participants treated with Wegovy® experienced substantial weight loss compared to the placebo group. During STEP 1, the average weight loss was approximately 15% over 68 weeks.


Whilst both Mounjaro and Wegovy® have demonstrated efficacious results when promoting weight loss, the specific extent of weight reduction and individual response can vary amongst individuals. Factors such as adherence to treatment, lifestyle modifications and baseline characteristics can influence the outcome or results. 

Mounjaro™ Vs Orlistat

Orlistat 120mg capsules are an effective weight loss medication used to treat obesity and reduce overall weight gain.

Through clinical trials, Orlistat was proven to block around one-third of all fat consumed with meals. Working directly in the stomach, Orlistat can help to make weight loss more effective than with a healthy diet and increased exercise alone.

Orlistat is prescription only, the body needs to break down dietary fats into smaller pieces before absorbing them. Orlistat works by obstructing the enzymes that break down the fats in your diet, halting the absorption process.

The obvious difference between Mounjaro™ and Orlistat is that you take Orlistat orally, whereas Mounjaro™ is injected. Orlistat also needs to be taken up to three times a day (after each meal) to get the best out of it meaning it is nowhere near as convenient as Mounjaro™, which is injected once weekly.

Mounjaro™ and Pregnancy

Mounjaro™ may cause fetal harm. When pregnancy is recognized, discontinue Mounjaro™. Discontinue Mounjaro™ in patients at least 2 months before a planned pregnancy.

Mounjaro™ Summary

How Mounjaro™ WorksStimulates hormone production and suppresses appetie
Efficacy83% of patients in clinical trial lost 5%+ of their body weight. Long term patients can lose up to 20% of body weight
How to Use Mounjaro™Injection, administered S.C into abdomen, thigh or upper arm once weekly
Common Side EffectsDiarrhoea, Nausea, Vomiting, Constipation

What is Active Ingredient?

Tirzepatide

Type of Medication

GIP and GLP-1 receptor agonist

Price

From £158.99

Mounjaro Alternatives

Available from February 2024, our service also offers other weight loss treatments. These include OrlistatSaxenda and Wegovy which is the most similar medicine to Mounjaro as it has a similar mechanism of action and is manufactured by Novo Nordisk.

Side Effects
Learn moreicon-arrow-right
Close

Mounjaro™ Side Effects

The most commonly reported side effects in clinical trials were:

  • Nausea (reported in 44% of patients)
  • Diarrhoea (reported in 30% of patients)
  • Vomiting (reported in 24% of patients)
  • Constipation (reported in 24% of patients) 

Other side effects included abdominal pain, headache, fatigue, and dizziness. 

In animal studies, semaglutide was associated with an increased risk of thyroid tumours. This link has not been determined in humans, but Wegovy should not be taken by people with a personal or family history of thyroid tumours or a condition called MEN-2.

Wegovy has been associated with other serious side effects like acute pancreatitis, gallbladder disease, heart rate increase and kidney injury. See the Wegovy information on side effects for further details.

Warnings
Learn moreicon-arrow-right
Close

Mounjaro™ Warning and Precautions

All medications come with risks when taken, even if minimal- the following is a comprehensive list of all potential complications, warning and precautions to be taken into consideration when being prescribed Wegovy™

  • Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging.
  • Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Acute pancreatitis was observed in patients treated with Wegovy™ in clinical trials. Observe patients carefully for signs and symptoms of acute pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting). If acute pancreatitis is suspected, discontinue Wegovy™ promptly, and if acute pancreatitis is confirmed, do not restart.
  • Acute Gallbladder Disease: In clinical trials, cholelithiasis was reported by 1.6% of Wegovy™ patients and 0.7% of placebo patients. Cholecystitis was reported by 0.6% of Wegovy™ patients and 0.2% of placebo patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
  • Hypoglycemia: Wegovy™ lowers blood glucose and can cause hypoglycemia. In a trial of patients with type 2 diabetes, hypoglycemia was reported in 6.2% of Wegovy™ patients versus 2.5% of placebo patients. Patients with type 2 diabetes taking Wegovy™ with an insulin secretagogue (e.g. sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms. Monitor blood glucose in patients with type 2 diabetes.
  • Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which in some cases required hemodialysis, in patients treated with semaglutide. Patients with renal impairment may be at a greater risk of acute kidney injury, but some events have been reported in patients without known underlying renal disease. A majority of the events occurred in patients who experienced nausea, vomiting, or diarrhea, leading to volume depletion. Monitor renal function when initiating or escalating doses of Wegovy™ in patients reporting severe adverse gastrointestinal reactions and in patients with renal impairment reporting any adverse reactions that could lead to volume depletion.
  • Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with semaglutide. If hypersensitivity reactions occur, discontinue use of Wegovy™, treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist.
  • Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: In a trial of patients with type 2 diabetes, diabetic retinopathy was reported by 4.0% of Wegovy™ patients and 2.7% of placebo patients. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
  • Heart Rate Increase: Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in Wegovy™ patients compared to placebo in clinical trials. More Wegovy™ patients compared with placebo had maximum changes from baseline of 10 to 19 bpm (41% versus 34%) and 20 bpm or more (26% versus 16%). Monitor heart rate at regular intervals and instruct patients to report palpitations or feelings of a racing heartbeat while at rest. If patients experience a sustained increase in resting heart rate, discontinue Wegovy™.
  • Suicidal Behavior and Ideation: Suicidal behavior and ideation have been reported in clinical trials with other weight management products. Monitor patients for depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Wegovy™ in patients who experience suicidal thoughts or behaviors and avoid in patients with a history of suicidal attempts or active suicidal ideation.

Patient Information Leaflet
Learn moreicon-arrow-right
Close

Mounjaro™ Weight Loss Injection Patient Information Leaflet

For more information about Mounjaro™, please take a look at the information leaflet below. It is important you read the Patient Information Leaflet (PIL) before using Mounjaro™.

Drug Interactions and Side Effects
Learn moreicon-arrow-right
Close

Mounjaro™ Drug Interactions

Like all medications, Wegovy™ has some drugs that will interact with it and the medication should not be used in this instance.

  • The addition of Mounjaro™ in patients treated with insulin has not been evaluated. When initiating Wegovy™, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.
  • Mounjaro™ causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with Mounjaro™.

Mounjaro™ Adverse Reactions

The most common adverse reactions reported involved the digestive system; arenausea, diarrhoea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease.

Mounjaro Dosage & Directions
Learn moreicon-arrow-right
Close

Mounjaro™ Dosage Guide

Mounjaro is a once-weekly injection and treatment must be initiated on the lowest dose of 2.5mg. Please see the below chart which gives a timeline on Mounjaro treatment.

Mounjaro Dosage Chart

Patients can stay on the lower doses if experiencing side effects, it is not mandatory to increase dose each 4 weeks if not being tolerated well or if satisifed with rate of weight loss. Always check in with a medical professional if concerned about side effects. Our team at Cloud Pharmacy are well trained on this new treatment. 

How to use Mounjaro™ Weight Loss Injection

Please watch this video on how to safely inject Mounjaro and read this guide for further instructions. 

In summary:

  • Decide where to inject the medication – abdomen or upper thigh. Rotating injection site each week. 
  • Carefully wash your hands using soap and water.
  • Prepare the pen and check that it’s not expired or damaged and the liquid looks as it should.
  • Attach a new needle to the pen.
  • Slowly turn the dose knob until you hear 2 clicks.
  • Prime the pen to release air bubbles and make sure it’s working correctly.
  • Adjust the dosage to "1".
  • Insert the needle, push down the dose knob and count slowly to 5.
  • Pull the needle out of your skin and check if the dose count is back at "0".
  • Remove the needle and replace the pen cap.

Is Mounjaro™ approved for Weight Loss?

Not only is Mounjaro (Tirzapetide) approved for weight loss in the UK by the MHRA (Medicines Healthcare Regulatory Authority) it is predominantly used in the treatment of Type 2 Diabetes in the NHS.

Related Guides

Delve into a variety of content written by our medical experts

Mounjaro Weight Loss Injection Reviews

Confirm Mounjaro Weight Loss Injection treatment selection

Starting Dose 2.5mg 1 Month £158.99
Starter Pack 2.5mg & 5mg 2 Month Starter Pack £300.00
5mg 1 Month £164.99
7.5mg 1 Month £174.00
10mg 1 Month £174.00
12.5mg 1 Month £209.00
15mg 1 Month £209.00
7089